Thursday, January 7, 2016

Vectura confirms Roxane laboratories as its partner for VR-315 (Advair copies) in the US

Vectura has confirmed that Roxane is the development and marketing partner for its drug VR-315 in the US. VR-315 is an inhaled drug that combines Fluticasone and Salmeterol, the same ingredient as GSK's Advair.
Roxane is a subsidiary of Boehringer Ingelheim which is a formidable player in the respiratory space in the US. The impact of launch of VR-315 in the US will have meaningful implications in the respiratory space. Both GSK and AstraZeneca should feel the pain of launch. Since VR-315 would directly compete with Advair, the extent of loss to Advair would be all the more meaningful.
The clinical trials comparing VR-315 to Advair are now complete and a filing in the US is on the cards. Prior to Roxane, Sandoz held  the rights for VR-315 in the US,  which it returned back to Vectura in 2010.